Synthesis, physico-chemical properties and penetration activity of alkyl-6-(2,5-dioxopyrrolidin-1-yl)-2-(2-oxopyrrolidin-1-yl)hexanoates as potential transdermal penetration enhancers

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 1, 2010, Pages 73-79

  Brychtova, Katerina ^a   Jampilek, Josef ^a,b   Opatrilova, Radka ^a   Raich, Ivan ^c   Farsa, Oldrich ^a   Csollei, Jozef ^a  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b Zentiva Prague   (Czech Republic)

^c INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

Lactam derivatives; 3D structures; 6 Aminohexanoic acid derivatives; Ab initio DFT calculations; Lipophilicity; Transdermal penetration enhancers

Indexed keywords

6 (2,5 DIOXOPYRROLIDIN 1 YL)HEXANOIC ACID; DECYL 6 (2,5 DIOXOPYRROLIDIN 1 YL) 2 (2 OXOPYRROLIDIN 1 YL)HEXANOATE; DOCECYL 6 (2,5 DIOXOPYRROLIDIN 1 YL) 2 (2 OXOPYRROLIDIN 1 YL)HEXANOATE; ETHYL 2 BROMO 6 (2,5 DIOXOPYRROLIDIN 1 YL)HEXANOATE; ETHYL 6 (2,5 DIOXOPYRROLIDIN 1 YL) 2 (2 OXOPYRROLIDIN 1 YL)HEXANOATE; HEPTYL 6 (2,5 DIOXOPYRROLIDIN 1 YL) 2 (2 OXOPYRROLIDIN 1 YL)HEXANOATE; HEXANOIC ACID DERIVATIVE; HEXYL 6 (2,5 DIOXOPYRROLIDIN 1 YL) 2 (2 OXOPYRROLIDIN 1 YL)HEXANOATE; NONYL 6 (2,5 DIOXOPYRROLIDIN 1 YL) 2 (2 OXOPYRROLIDIN 1 YL)HEXANOATE; OCTYL 6 (2,5 DIOXOPYRROLIDIN 1 YL) 2 (2 OXOPYRROLIDIN 1 YL)HEXANOATE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNDECYL 6 (2,5 DIOXOPYRROLIDIN 1 YL) 2 (2 OXOPYRROLIDIN 1 YL)HEXANOATE;

ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PENETRATION; DRUG SYNTHESIS; HYDROPHOBICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIPOPHILICITY; MASS SPECTROMETRY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRATUM CORNEUM; STRUCTURE ACTIVITY RELATION;

6-AMINOCAPROIC ACID; ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG CARRIERS; LIPIDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PERMEABILITY; SKIN; SKIN ABSORPTION; SWINE; THEOPHYLLINE;

EID: 72049085249     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.11.020     Document Type: Article

References (47)

1. Smith E.W., and Maibach H.I. Percutaneous Penetration Enhancers. 2nd ed. (2006), CRC Press, Boca Raton, FL, USA
2. Thong H.-Y., Zhai H., and Maibach H.I. Skin. Pharmacol. Physiol. 20 (2007) 272
3. Williams A.C., and Barry B.W. Adv. Drug Delivery Rev. 56 (2004) 603
4. Benson H.A.E. Curr. Drug Delivery 2 (2005) 23
5. Finnin B.C., and Morgan T.M. J. Pharm. Sci. 88 (1999) 955
6. Yamato K., Takahashi Y., Akiyama H., Tsuji K., Ohnishi H., and Machida Y. Biol. Pharm. Bull. 32 (2009) 677
7. Barry B.W. J. Controlled Release 15 (1991) 237
8. Moser K., Kriwet K., Naik A., Kalia Y.N., and Guy R.H. Eur. J. Pharm. 52 (2001) 103
9. Zhai H., and Maibach H.I. Skin Pharmacol. Appl. Skin Physiol. 14 (2001) 1
10. Zhai H., and Maibach H.I. Contact Dermatitis 44 (2001) 201
11. Sinha V.R., and Kaur M.P. Drug Dev. Ind. Pharm. 26 (2000) 1131
12. Hadgraft J., Peck J., Williams D.G., Pugh W.J., and Allan G. Int. J. Pharm. 141 (1996) 1725
13. Lopez-Cervantes M., Marquez-Mejia E., Cazares-Delgadillo J., Quintanar-Guerrero D., Ganem-Quintanar A., and Angeles-Anguiano E. Drug Dev. Ind. Pharm. 32 (2006) 267
14. Williams A.C., and Barry B.W. Crit. Rev. Ther. Drug Carr. Syst. 9 (1992) 305
15. Dolezal P., Hrabalek A., and Semecky V. Pharm. Res. 10 (1993) 1015
16. Pugh W.J., Wong R., Falson F., Michniak B.B., and Moss G.P. J. Pharm. Pharmacol. 57 (2005) 1389
17. Zheng T., Hopfinger A.J., Esposito E.X., Liu J., and Tseng Y.J. J. Chem. Inf. Model. 48 (2008) 1238
18. Ghafourian T., Zandasrar P., Hamishekar H., and Nokhodchi A. J. Controlled Release 99 (2004) 113
19. Barry B.W. J. Controlled Release 6 (1987) 85
20. Kim N., El-Kattan A.F., Asbill C.S., Kennette R.J., Sowell J.W., Latour R., and Michniak B.B. J. Controlled Release 73 (2001) 183
21. Baert B., Deconinck E., Van Gele M., Slodicka M., Stoppie P., Bode S., Slegers G., Vander Heyden Y., Lambert J., Beetens J., and De Spiegeleer B. Bioorg. Med. Chem. 15 (2007) 6943
22. Pliska V. Lipophilicity in Drug Action and Toxicology. In: Pliska V., Testa B., and van der Waterbeemd H. (Eds). Methods and Principles in Medicinal Chemistry. 1st ed. Vol. 4 (1996), Wiley-VCH, Weinheim 1-6
23. Franz T.J. J. Invest. Dermatol. 64 (1975) 190
24. Schwenk E., and Papa D. J. Am. Chem. Soc. 70 (1948) 3626
25. Berry J.P., Isbell A.F., and Hunt G.E. J. Org. Chem. 37 (1972) 4396
26. Brychtova K., Slaba B., Placek L., Jampilek J., Raich I., and Csollei J. Molecules 14 (2009) 3019
27. Otera J. Chem. Rev. 93 (1993) 1449-1470 and references cited therein
28. Karande P., Jain A., Ergun K., Kispersky V., and Mitragotri S. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 4688
29. Scrocco E., and Tomasi J. Top. Curr. Chem. 42 (1973) 95
30. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Montgomery, Jr., J.A.; Vreven, T.; Kudin, K.N.; Burant, J.C.; Millam, J.M.; Iyengar, S.S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G.A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J.E.; Hratchian, H.P.; Cross, J.B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R.E.; Yazyev, O.; Austin, A.J.; Cammi, R.; Pomelli, C.; Ochterski, J.W.; Ayala, P.Y.; Morokuma, K.; Voth, G.A.; Salvador, P.; Dannenberg, J.J.; Zakrzewski, V.G.; Dapprich, S.; Daniels, A.D.; Strain, M.C.; Farkas, O.; Malick, D.K.; Rabuck, A.D.; Raghavachari, K.; Foresman, J.B.; Ortiz, J.V.; Cui, Q.; Baboul, A.G.; Clifford, S.; Cioslowski, J.; Stefanov, B.B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R.L.; Fox, D.J.; Keith, T.; Al-Laham, M.A.; Peng, C.Y.; Nanayakkara, A.; Challacombe, M.; Gill, P.M.W.; Johnson, B.; Chen, W.; Wong, M.W.; Gonzalez, C.; Pople, J.A. gaussian 03, Revision D.01, Gaussian: Wallingford CT, USA, 2004.
31. Barone V., and Cossi M. J. Phys. Chem. A 102 (1998) 1995
32. Ni N., El-Sayed M.M., Sanghvi T., and Yalkowsky S.H. J. Pharm. Sci. 89 (2000) 1620
33. Katz M., Ben-Shlush I., Kolusheva S., and Jelinek R. Pharm. Res. 23 (2006) 580
34. Fang J.-Y., Tsai T.-H., Hung C.-F., and Wong W.-W. J. Pharm. Pharmacol. 56 (2004) 1493
35. Klimentova J., Kosak P., Vavrova K., Holas T., and Hrabalek A. Bioorg. Med. Chem. 14 (2006) 7681
36. Sloan K.B., Beall H.D., Taylor H.E., Getz J.J., Villaneuva R., Nipper R., and Smith K. Int. J. Pharm. 171 (1998) 185
37. Evrard D., Touitou E., Kolusheva S., Fishov Y., and Jelinek R. Pharm. Res. 18 (2001) 943
38. Williams A.C., and Barry B.W. Int. J. Pharm. 56 (1989) 43
39. Yamane M.A., Williams A.C., and Barry B.W. J. Pharm. Pharmacol. 47 (1995) 978
40. Jacobi U., Kaiser M., Toll R., Mangelsdorf S., Audring H., Otberg N., Sterry W., and Lademann J. Skin Res. Technol. 13 (2007) 19
41. Herkenne C., Naik A., Kalia Y.N., Hadgraft J., and Guy R.H. Pharm. Res. 23 (2006) 1850
42. Meyer W., Schwarz K., and Neurand K.T. Curr. Probl. Dermatol. 7 (1978) 39
43. Wilkinson S.C., Maas W.J.M., Nielsen J.B., Greaves L.C., Sandt J.J.M., and Williams F.M. Int. Arch. Occup. Environ. Health 79 (2006) 405
44. Bronaugh R.L., and Maibach H.I. In Vitro Percutaneous Absorption: Principles, Fundamentals, and Applications (1991), CRC Press, Boca Raton, FL, USA
45. Crutcher W., and Maibach H.I. J. Invest. Dermatol. 53 (1969) 264
46. Reifenrath W.G., Lee B., Wilson D.R., and Spencer T.S. J. Pharm. Sci. 83 (1994) 1229
47. Rowat A.C., Kitson N., and Thewalt J.L. Int. J. Pharm. 307 (2006) 225